QQQ0.32%

Trending

XLM23.00%

home Symbol MIRMnews

MIRM
Mirum Pharmaceuticals Inc

1,641

Mkt Cap

$6.07B

Volume

1.37M

52W High

$114.99

52W Low

$43.50

PE Ratio

-7.46

MIRM Fundamentals

Price

$101.50

Prev Close

$99.60

Open

$99.72

50D MA

$97.09

Beta

0.86

Avg. Volume

619,359.14

EPS (Annual)

-$0.4654

P/B

25.50

Rev/Employee

$1.4M

$3,901.29

Info

News

all

press releases

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress 2026, taking place May 27-30, 2026, in Barcelona, Spain. Presentations span Mirums...

Business Wire

More News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 22,950 shares of common stock and 31,300...

Business Wire

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible...

Business Wire

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the notes) in a private placement (the...

Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026 Company fireside chat starting at 3:30 p.m. ET 2026...

Business Wire

Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Zacks

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings

Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +3.47% and +8.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the first quarter 2026 and provided a business update. 2026 is off to an excellent...

Business Wire

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High After Analyst Upgrade

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High on Analyst Upgrade...

MarketBeat

...